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Genetically Engineered Human Mesenchymal Stem Cells Produce
Met-Enkephalin at Augmented Higher Levels In Vitro
Ikuko Sugaya,* Tingyu Qu,† Kiminobu Sugaya,* and George D. Pappas†
*Biomolecular Science Center, Burnett College of Biomedical Sciences,
University of Central Florida, Orlando, FL 32816-2364, USA
†The Psychiatric Institute, Department of Psychiatry, and Department of Anatomy and Cell Biology,
University of Illinois at Chicago, Chicago, IL 60612, USA
We have reported that transplantation of adrenal medullary chromaffin cells that release endogenous opioid
peptides into pain modulatory regions in the CNS produce significant antinociceptive effects in patients with
terminal cancer pain. However, the usefulness of this procedure is minimal because the availability of human
adrenal tissue is very limited. Alternative xenogeneic materials, such as porcine and bovine adrenal chromaf-
fin cells present problems of immune rejection and possible pathogenic contamination. In an attempt to
develop opioid peptide-producing cells of autologous origin, we have transfected human mesenchymal stem
cells (hMeSCs) with a mammalian expression vector containing a fusion gene of green fluorescent protein
(GFP) and human preproenkephalin (hPPE), a precursor protein for enkephalin opioid peptides. Enkephalins
are major neurotransmitters that play an important role in analgesia by activating peripheral opioid receptors.
Following the establishment of stable transfection of hMeSCs, the expressions of hPPE and GFP were
confirmed and the production of methionine enkephalin (Met-enkephalin) was significantly increased com-
pared to control naive hMeSCs (p < 0.05). Our in vitro data demonstrated that genetically engineered
hMeSCs with transfected hPPE gene can constitutively produce opioid peptide Met-enkephalin at an aug-
mented high level. hMeSCs are relatively easy to isolate from a patient’s bone marrow aspirates and expand
in culture by repeated passages. Autologous hMeSCs would not require immunosuppression when trans-
planted back into the same patient. Through targeted gene manipulation such as hPPE gene transfection, this
may offer a virtually unlimited safe cell supply for the treatment of opioid-sensitive pain in humans.
Key words: Preproenkephalin; Gene transfection; Human mesenchymal stem cells; Autologous source;
Enkephalins; Antinociception
INTRODUCTION cal need for suitable sources of chromaffin cells is obvi-
ous. Bovine or porcine adrenal medullary tissue may
provide alternative cell sources; however, these cellsPrevious studies have shown that transplantation of
xenogeneic adrenal medullary tissue or isolated chro- elicit host immunological response to the transplants
(2,7). Immunosuppression is necessary for the prolongedmaffin cell suspensions into the spinal subarachnoid
space produces antinociception in rats and in nonhuman survival of the transplants, and immunosuppression may
result in serious problems, including an increased sus-primates (7,17,18,20). Initial clinical trials using alloge-
neic adrenal chromaffin tissue provided pain relief in ceptibility to tumor growth and infections. Although
chromaffin cells are not very immunogenic and purifiedpatients with terminal cancer (4,11,26). Adrenal medu-
lary chromaffin cells synthesize and release several com- xenogeneic chromaffin cells can minimize immunore-
jection, even a small number of passenger cells (i.e., fi-pounds, including enkephalins and catecholamines (5,23).
These agents reduce pain sensitivity when injected di- broblast and endothelial cells) in the transplant prepara-
tion are highly immunogenic (2,10). In our experiencerectly into the spinal cord subarachnoid space (7,16,17).
However, availability of human adrenal tissue to serve with purified chromaffin cell transplants, a clear de-
crease in transplant function over time occurs (7). Foras allografts for transplantation is very limited. Because
effective therapy of a single patient requires large amounts example, with xenogeneic chromaffin cell transplants,
the attenuation of pain may last only 3 weeks withoutof isolated chromaffin cells for transplantation, the clini-
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immunosuppression (7), while analgesia can last longer cells were incubated at 37°C in a 5% CO2 humidified
incubation chamber (Fisher, Pittsburgh, PA). The cells(at least 5 weeks) with immunosuppression (20). The
reasons for the gradual decline in analgesic effect are were fed by replacing half the culture medium twice per
week.not yet clear; it may involve several factors in which
immunorejection cannot be excluded, because the ad-
Transfection of Human Preproenkephalin (hPPE)ministration of immunosuppression itself enhances longer
term graft survival and extends the analgesic effect The hPPE cDNA (pGEMhPPE) was a gift from Dr.
S. P. Wilson (University of South Carolina, School of(7,9). In addition, there has been a concern regarding
pathogen contamination of bovine spongiform encepha- Medicine, Department of Pharmacology, Physiology and
Neuroscience). The hPPE cDNA was dissected out fromlopathy for bovine chromaffin cell transplantation. There-
fore, the ideal cell source would be autologous cells de- pGEMhPPE by digestion with EcoRI and HindIII. The
hPPE cDNA was purified on a gel (960 bp) and thenrived from the patient’s own tissue.
With the advance of in vitro gene technology, there ligated into EcoRI and HindIII site of pcDNA3.1(−)/Zeo
(Invitrogen), human cytomegalovirus (CMV) promoter-is a potential for genetically engineering the cells de-
rived from a patient’s own peripheral tissue for targeted based constitutive expression vectors [pcDNA3.1(−)/zeo/
hPPE]. To produce enhanced green fluorescent proteinclinical use (12,13,21,24,25). Autologous human mesen-
chymal stem cells (hMeSCs) are relatively easy to iso- (EGFP) fusion hPPE, pcDNA3.1(−)/zeo/hPPE was di-
gested by XhoI and HindIII and the resulting fragmentlate from bone marrow aspirates and then expand in cul-
ture by repeatable passages. These cells are favorable (993 bp) was cloned into the pEGFP (BD Bioscience,
Palo Alto, CA) XhoI and HindIII site (pEGFP/hPPE).candidates for further genetic manipulation because they
are able to proliferate and potentially differentiate into All the clones were confirmed by DNA sequencing. En-
dotoxin-free plasmids are prepared by NucleoBond Plas-the cell lineage of various types including neural pheno-
types and survive for prolonged period when trans- mid EF Kit (BD Bioscience) from bacterial cultures.
Transfection of the gene to the hMeSCs was performedplanted into the CNS (1,14,19,27). Preproenkephalin
(PPE) is the precursor protein for enkephalins and en- by using NeuroPORTOR (Gene Therapy Systems, Inc.,
San Diego, CA) by following the protocol provided bykephalin opioid peptides such as Met- and Leu-enkepha-
lin, which are important neurotransmitters for inhibition the manufacturer. After the transfection, GFP expression
was checked with a Leica fluorescent microscope.of nociception (3,5,6,15,25). Following transfection, the
expression of human PPE (hPPE) and green fluorescent
Gene Expression Analysis by RT-PCRprotein (GFP) genes and the production of Met-enkepha-
lin in MeSCs were examined by RT-PCR and an immu- Four days after transfection, hPPE and GFP gene ex-
pressions were analyzed by RT-PCR. RNAs were iso-noblot assay, respectively. Our results demonstrated that
these genetically engineered hMeSCs have an enhanced lated from the cells using TRIzol reagent (Invitrogen)
and treated with RNAase-free DNAase (Promega, Madi-hPPE gene expression and increased release of Met-
enkephalin in culture conditions. As a first step, we have son, WI). RT-PCR was performed using SuperScript
One-Step RT-PCR with Platinum Taq (Invitrogen) usingsuccessfully manipulated hMeSCs genetically to pro-
duce more opioid peptide Met-enkephalin by targeted gene-specific primer sets: hPPE (5′-ACATCAACTTCC
TGGCTTGCGT-3′ and 5′-GCTCACTTCTTCCTCATTgene transfection. hMeSCs are dividing cells and prolif-
erate in culture with repeated passages. These autolo- ATCA-3′), GFP (5′-CAAGGACGACGGCAACTACA
AGACC-3′ and 5′-GCGGACTGGGTGCTCAGGTAGTgous Met-enkephalin-producing hMeSCs may offer a
virtually unlimited safe cell supply and have promise of GGT-3′). DNA samples resulting from RT-PCR were
analyzed on 2% E-Gel (Invitrogen).serving as a useful alternative to adrenal chromaffin
cells for the clinical treatment of opioid-sensitive pain.
Immunoblot Assay for Met-Enkephalin
MATERIALS AND METHODS in the Culture Media
Cell Cultures The serum-supplemented growth medium for hMeSCs
was replaced by serum-free medium (DMEM with anti-hMeSCs were purchased from Cambrex (Walkers-
ville, MD), which were negative for CD11b, CD33, biotic-antimycotic) 1 day before Met-enkephalin assay.
Twenty-four hours later, medium was collected and pu-CD34, and CD133 antigens. hMeSCs were cultured in
75-cm2 culture flasks (Corning, Cambridge, MA) in 20 rified with YM-30 microcon (Millipore Corp., Bedford,
MA). Filtered sample (200 µl) and Met-enkephalin stan-ml of serum-supplemented growth medium consisting of
Dulbecco’s modified Eagle medium (Invitrogen, Carls- dards (50–1000 ng/slot, Phoenix Pharmaceuticals, Inc.,
Belmont, CA) were applied on Hybond ECL nitrocellur-bad, CA), antibiotic-antimycotic mixture (Invitrogen),
and FBS (Stem Cell Technologies, Vancouver, BC). The ose membrane (Amersham Life Science, Piscataway,
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NJ) using the Slot Blot Hybridization Manifold (GENE
Mate, Kaysville, UT). The membranes were blocked
with 3% normal donkey serum (Jackson ImmunoResearch,
West Grove, PA) in phosphate-buffered saline contain-
ing 0.5% Tween 20 (PBST) for 2 h at room temperature.
The membranes were then incubated with Met-enkepha-
lin antibody made in rabbit (1:600, ImmunoStar Inc.,
Hudson, WI) for overnight at 4°C. After washing with
PBST three times, the membranes were incubated with
anti-rabbit IgG peroxidase-linked species-specific whole
donkey antibody (1:3000, Amersham Biosciences) for
90 min at room temperature. The membranes were
washed with PBS, incubated with ECL Plus detection
reagent (Amersham Biosciences) for 5 min, and then ex-
posed to Hyperfilm ECL (Amersham Biosciences). The
films were developed, digitally scanned into a computer,
and analyzed with NIH image (ImageJ, NIH). The data
were normalized against cell numbers, which were
counted using Bright-Line Hemacytometer (Hausser
Scientific, Horsham, PA).
RESULTS
The hMeSCs transfected with GFP/hPPE fused gene
were grown at 37°C for 24 h before in vitro analysis.
These cells retained their ability to proliferate at a speed
similar to that of the hMeSCs without gene transfection.
Under the culture condition as mentioned above, these
cells can double themselves by 7 days.
Figure 1. RT-PCR detection of GFP and hPPE expression in
RT-PCR Analysis hMeSCs after gene transfection. Lane a: GFP and hPPE gene
transfected hMeSCs showed GFP (318 bp) and hPPE expres-Four days after transfection with GFP/hPPE fused
sion (425 bp). Lane b: Nontransfected hMeSCs showed hPPE
gene, hMeSCs expressed both GFP and hPPE, which expression (425 bp) alone. Lane c: DNA ladder (100 bp).
was analyzed by RT-PCR. As expected, the molecular
size of the RT-PCR product for hPPE and GFP gene
fragments was 425 and 318 bp, respectively. Naive when compared with naive hMeSCs (p < 0.05) (Fig.
hMeSCs expressed hPPE; however, transfection of GFP/ 2Fig. 2). Following transfection of GFP/hPPE/, GFP ex-
hPPE into hMeSCs greatly enhanced hPPE gene expres- pression of hMeSCs was detected as green fluorescence-
sion in these cells (Fig. 1). labeled cells under fluorescence microscope (Fig. 3).
Production and Release of Met-Enkephalin DISCUSSION
Our present study demonstrates that hMeSCs trans-The serum-supplemented growth medium for hMeSCs
was replaced by serum-free medium (DMEM with anti- fected with a vector containing a fused hPPE and GFP
gene were able to express both hPPE and GFP genesbiotic-antimycotic) 1 day before immunoblot assay for
Met-enkephalin. Twenty-four hours later, medium was and constitutively produce a high level of Met-enkepha-
lin opioid peptide in cell culture. As assessed by RT-collected and purified for immunoblot assay. Naive
hMeSCs were able to produce and release of Met- PCR and an immunoblot assay, our results reveal that
naive hMeSCs have an inherent but weak PPE gene ex-enkephalin opioid peptide into the culture medium at a
basal level of 1.731 ± 0.124 pg/cell/24 h. Then we as- pression and are spontaneously able to release a basal
level of Met-enkephalin at a rate of 1.731 ± 0.124 pg/sessed whether the transgenic GFP/hPPE were able to
drive the production and secretion of Met-enkephalin cell/24 h in the cultured condition. Four days after hPPE
gene transfection, hMeSCs obtained an enhanced hPPEopioid peptide in the transfected hMeSC population. We
found that the gene transfected hMeSCs had a signifi- expression and the production of Met-enkephalin signif-
icantly increased at a rate of 2.42 ± 0.46 pg/cell/24 hcantly augmented production and release of Met-enkepha-
lin opioid peptide at a rate of 2.42 ± 0.46 pg/cell/24 h, (p < 0.05) (Fig. 3). Therefore, genetic enhancement of
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peptides released by the transplanted cells because it can
be blocked by intrathecal administration of the opioid
antagonist naloxone. These results suggest that the ge-
netically engineered cells expressing hPPE and produc-
ing Met-enkephalin have promise to serve as a useful
alternative to adrenal chromaffin cells in pain treatment.
As reported previously, transplantation of xenogenic
adrenal medullary tissue or isolated medullary chromaf-
fin cell suspensions into the pain modulatory regions in
the CNS can produce robust antinociceptive effect in an-
imal pain models (16,18,20). Preliminary clinical trials
using allogenic adrenal medullary tissue produced a
long-term analgesic effect in patients with refractory
cancer pain without development of tolerance (4,11,26).
Beside the limited availability of allogeneic adrenal tis-
sue and the lack of tissue for individual transplantation,
there is a concern regarding immunorejection and patho-
gen contamination for adrenal tissues of xenogeneic
sources (2,7). It would be ideal to develop a new source
of autologous cells derived from the patient’s own pe-
ripheral tissue because the cells of an autologous origin
would not require immune suppression when trans-
planted back to the same patient. Our present study dem-
onstrated that hMeSCs could be a favorable autologous
cell candidate for generating chromaffin cell-like cells
through further gene manipulation because these cells
Figure 2. Met-enkephaline production of naive hMeSCs and inherently express hPPE gene and are able to spontane-hMeSCs transfected with EGFP/hPPE gene. Note the signifi-
ously release low level of opioid peptide Met-enkeph-cantly increased met-enkephalin production in the culture of
alin.hMeSCs transfected with EGFP/hPPE gene (*p < 0.05).
Wilson and colleagues and others (3,6,15,25) have
introduced the hPPE gene to sensory neurons by a her-
pes-mediated gene delivery system that successfullyhMeSCs by targeted hPPE gene transfection signifi-
cantly increased their ability to produce more Met- modulates certain types of nociceptive reactions in ex-
perimental pain models. In an effort to develop a newenkephalin. In accordance with naive MeSCs, the genet-
ically enhanced Met-enkephalin-producing hMeSCs source of chromaffin-like cells from an autologous source
of cells, we genetically transfected hMeSCs with awere stable and retained their ability to proliferate in
vitro, suggesting that these cells are both viable and mammalian expression vector containing a fused gene
of hPPE and enhanced GFP and successfully generatedfunctional. Thus, we have successfully generated ex-
pandable hMeSCs into Met-enkephalin opioid peptide- hMeSCs opioid peptide Met-enkephalin-producing cells
without viral delivery. Because autologous hMeSCs areproducing cells, which can release Met-enkephlin at the
similar levels to normally found in the primary chromaf- easily isolated from patients’ own peripheral tissues and
are expandable in cell culture for further gene manipula-fin cells.
We have previously briefly described a similar ap- tion, our approach may provide a favorable alternative
to adrenal chromaffin cell transplantation in the treat-proach of hPPE gene transfection into human neuron-
committed teratocarcinoma (NT-2) cells (8). These gene ment of opioid-sensitive chronic pain, a treatment that
will not cause host immune rejection and thereby im-transfected NT-2 cells expressed hPPE gene and pro-
duce Met-enkephalin. A subpopulation of them can be proving analgesic efficacy. By avoiding the use of viral
vectors as a vehicle to deliver a target gene into painterminally differentiated into neurons by retinoic acid
treatment. When transplanted intrathecally into a rat modulatory regions, the strategies of in vitro gene ma-
nipulation of autologous cells may hold the promise ofpain model, the differentiated neuronal cells derived
from NT-2 cells transfected with hPPE gene demon- providing safer and more efficacious approaches for tar-
geted clinical application.strated antinociception at an efficacy similar to that ob-
served with chromaffin cell transplantation (8). The re- The hMeSCs are able to proliferate and have the po-
tential to differentiate into the cell lineage of variousduced pain sensitivity is obviously mediated by opioid
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Figure 3. Picture showing the enhanced green fluorescent protein (EGFP) expression in the cyto-
plasm of the hMeSCs transfected with a fused gene of EGFP/hPPE under the fluorescence micro-
scope (×400).
types, including the ability of acquiring neural pheno- mental data about the therapeutic potential of autologous
hMeSCs transfected by hPPE gene in pain treatment.types both in vitro and in vivo and surviving for pro-
longed periods when transplanted into the brain (1,14, We demonstrated that naive hMeSCs have a low level
of endogenous hPPE gene expression and low level of19,27), suggesting the feasibility of hMeSCs for CNS
transplantation. After gene transfection, these cells re- Met-enkephalin production and that gene-enhanced
hMeSCs by hPPE transfection are able to constitutivelytained the capacity for proliferation and differentiation.
These properties of hMeSCs make them valuable when produce Met-enkephalin and spontaneously release Met-
enkephalin at a high level in the cell culture. The hPPEthey are used as vehicles for the release of neuroactive
substances into the host CNS environment and function expression was confirmed by RT-PCR, and the level of
Met-enkephalin production was examined by an immu-as a biological pump, providing an endogenous source
of renewable neuroactive substances. noblot assay. The data obtained from our studies suggest
that hMeSCs transfected with hPPE gene without viralUnlike chromaffin cells, which are postmitotic,
hMeSCs are self-renewal stem cells. Because these ge- delivery may serve as a suitable alternative to adrenal
chromaffin cells for transplantation to control chronicnetically engineered hMeSCs can multiply in culture
over repeated passages, this source of cells may offer a pain.
sufficient cell supply for the need of transplantation. Our ACKNOWLEDGMENTS: This study was supported by NIH
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